GHRP-2 + Ipamorelin Blend
Fat LossGHS combination / researchExperimental
Blend of two ghrelin-receptor agonists. Both GHRP-2 (pralmorelin) and ipamorelin are WADA S2. Not FDA-approved as a combination.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- Mixture
- Half-life
- Short; both ~1–2 h combined activity
- Unit
- mcg
- Administration Route
- Subcutaneous (research)
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- GHSR
Overview
Blend of two ghrelin-receptor agonists. Both GHRP-2 (pralmorelin) and ipamorelin are WADA S2. Not FDA-approved as a combination.
Protocol
- Dosage Range
- Not established
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous (research)
- Reconstitution Guide
- —
Science
Mechanism of Action
Both peptides activate GHSR; combining them does not add a new receptor class and may increase GH and cortisol/prolactin (GHRP-2) versus ipamorelin alone.
Targets
GHSR
Studies
- GHRP-2 diagnostic / secretagogue literature— Journal/year not available
Benefits
GH-axis research blend
Potential Side Effects
- Hunger
- Cortisol/prolactin rise from GHRP-2
- Water retention
References
- PMID 11081185External link · Year —
- WADA Prohibited List 2026External link · Year —